Biological agents have extremely broad application prospects in the field of immune-related therapy. As a reputable senior supplier, Creative Biolabs offers customized IgD antibody research and development services to provide accurate information on IgD-related autoimmune diseases.
Introduction of IgD
Immunoglobulin D (IgD) is composed of two identical light chains and two heavy chains. There are two types of IgD: secreted IgD (sIgD) and membrane-bound IgD (mIgD), both of which exert important immunological functions. In addition, mIgD is an important feature of mature B cells. Abnormally elevated IgD levels are closely linked to the inflammatory response. Although the content of IgD in the body is very low, it plays a vital role in autoimmune diseases. There is increasing evidence that IgD may be involved in the occurrence of some autoimmune diseases, such as Rheumatoid arthritis (RA), Sjogren’s syndrome (SS) and systemic lupus erythematosus (SLE).
Typical Autoimmune Disease-RA
RA is the most common chronic systemic autoimmune disease that leads to restricted mobility and is characterized by joint inflammation, synovial hyperplasia, cartilage degeneration, and bone erosion. Among them, synovitis is the main pathological manifestation. The pathogenesis of RA is related to the abnormal activation of T cells and B cells. A large number of activated CD4+ T cells infiltrate the synovial tissue and secrete inflammatory cytokines that cause inflammation of the RA synovium. Currently, the main treatments for RA include disease-relieving anti-rheumatic drugs (DMARDs), non-steroidal anti-inflammatory drugs (NSAIDs) and biological agents. However, these drugs can cause gastrointestinal side effects, liver toxicity, bone marrow suppression and many other adverse reactions, which seriously hinder the therapeutic effect. Therefore, it is necessary to explore and identify RA treatment targets and develop new RA treatment drugs.
Add comment
Comments